Supplemental Digital Content

**Figure S1. ISR incidence over time through Month 12a**



aIncidence is derived relative to the number of participants who received injections at each respective study visit. There were no Grade 3 or Grade 4 ISRs.

Figure S1 was presented previously at IDWeek; October 21–25, 2020; Virtual; Oral.

ISR, injection site reaction; Q2M, every 2 months.

**Figure S2. Mean HIVTSQca individual item scores at Month 12**

 

aIndividual HIVTSQc items are rated on a 6-point Likert scale, ranging from –3 (much less satisfied now) to 3 (much more satisfied now).

CAB, cabotegravir; DTG, dolutegravir; HIVTSQc, HIV Treatment Satisfaction Questionnaire change version; LA, long-acting; RPV, rilpivirine.

**Table S1. Efficacy outcomes at Month 12**

|  |  |  |
| --- | --- | --- |
| **Outcome, n (%)** | **IM CAB+RPV LA****Q2M arm****n=90** | **Oral DTG/RPV QD arm****n=7** |
| HIV-1 RNA ≥50 copies/mL | 0 | 0 |
| HIV-1 RNA <50 copies/mL | 88 (97.8) | 7 (100) |
| Data in window not below threshold | 0 | 0 |
| Discontinued for lack of efficacy | 0 | 0 |
| Discontinued for other reason while not below threshold | 0 | 0 |
| Change in background therapy | 0 | 0 |
| No virologic data | 2 (2.2) | 0 |
| Discontinued due to AE | 1 (1.1)a | 0 |
| Discontinued due to death | 0 | 0 |
| Discontinued study for other reason | 1 (1.1)b | 0 |
| On study but missing data in window | 0 | 0 |

aParticipant discontinued due to a drug-related AE of depression.

bParticipant was lost to follow-up.

Table S1 was presented previously at IDWeek; October 21–25, 2020; Virtual; Oral.

AE, adverse event; CAB, cabotegravir; DTG, dolutegravir; IM, intramuscular; LA, long-acting; QD, once daily; Q2M, every 2 months; RPV, rilpivirine.

**Table S2. ISR overview**

|  |  |
| --- | --- |
| **Parameter** | **IM CAB+RPV LA Q2M arm n=90** |
| Number or participants receiving injections, n | 90 |
| Number of injections, n | 1534 |
| ISR events,a n  | 463  |
| Pain, n (% of injections) | 414 (27) |
| Discomfort, n (% of injections) | 20 (1) |
| Swelling, n (% of injections) | 11 (<1) |
| Nodule, n (% of injections) | 6 (<1) |
| Grade ≥3 ISR events, n | 0 |
| Median (IQR) duration of ISRs, days | 3 (2, 4) |
| Withdrawals due to ISR or injection intolerability, n (%) | 0 |

aOnly ISRs with an incidence of >5 events are listed.

Table S2 was presented previously at IDWeek; October 21–25, 2020; Virtual; Oral.

CAB, cabotegravir; IM, intramuscular; ISR, injection site reaction; IQR, interquartile range; LA, long-acting; Q2M, every 2 months; RPV, rilpivirine